GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

Walmsley stated that GSK's renewed focus on oncology is a strategic move to expand its specialty medicines portfolio. The company has plans to advance the IDRx drug to late-stage trials within the ...

GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm's prospects at an investor meeting last week would deflect criticism of her leadership from ...

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

Emma Walmsley needs to convince shareholders she has the right plan. The boss of GlaxoSmithKline faces one of the biggest challenges of her career as she tries to convince shareholders in the ...

GlaxoSmithkline chief executive Emma Walmsley was made a dame for services to the pharmaceutical industry. The drugs firm is one of about 20 that is part of a global race to develop a coronavirus ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...